| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
The primary target of NVX-207 is the apoptosis pathway. It induces apoptosis through activation of the intrinsic apoptotic pathway. This involves cleavage of caspases -9, -3, and -7, as well as PARP, leading to programmed cell death. Its anti-cancer activity is mediated through this pro-apoptotic mechanism.
|
|---|---|
| ln Vitro |
NVX-207 uses apoptosis to cause cell death [1]. With IC50 values ranging from 7.6-8.5 µM, NVX-207 was found to be highly cytotoxic against the three malignant glioma cell lines under investigation. NVX-207 reduces survivin expression levels and cleaves PARP in both normoxic and hypoxic environments. In glioma cell lines, NVX-207 (20 µM) significantly raises the necrosis rate [2].
In vitro, NVX-207 has high cytotoxicity in the three analyzed malignant glioma cell lines with IC50 values ranging from 7.6-8.5 μM. It shows anti-tumor activity with a mean IC50 of 3.5 μM against various human and canine cell lines. At 20 µM, it causes a significantly high rate of necrosis of glioma cell lines. It decreases cell death via apoptosis. |
| ln Vivo |
Mice responded favorably to NVX-207 intravenous treatment [1].
In vivo, NVX-207 has been studied for its anti-cancer activity. It shows anti-tumor activity against various human and canine cell lines. Its improved solubility and enhanced pro-apoptotic potency enable consistent topical and transdermal oncology research. Specific in vivo animal model data is not extensively detailed in the available literature, but its activity suggests potential efficacy in xenograft models. |
| Enzyme Assay |
In vitro enzyme/receptor binding assays for NVX-207 are not extensively described. As a betulinic acid derivative, its mechanism involves direct activation of the intrinsic apoptotic pathway rather than binding to a specific enzyme or receptor. Studies typically focus on measuring caspase activity and PARP cleavage in cell lysates using fluorogenic substrates or western blotting to assess its pro-apoptotic effects.
|
| Cell Assay |
In vitro cellular assays for NVX-207 are conducted in various cancer cell lines, including malignant glioma cell lines. Cells are treated with the compound, and cell viability is measured using MTT or similar assays to determine IC50 values. Apoptosis is evaluated by measuring caspase-9, -3, -7 activity and PARP cleavage. Necrosis is assessed using specific staining methods.
|
| Animal Protocol |
In vivo animal studies for NVX-207 would likely involve mouse xenograft models using cancer cell lines sensitive to the compound. Animals would be administered the compound topically, transdermally, or systemically, and tumor growth inhibition would be monitored. The compound's ability to induce apoptosis and its effects on tumor tissue would be assessed by immunohistochemistry or western blotting.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of NVX-207 indicate it has a molecular weight of 601.86 and a molecular formula of C36H59NO6. It is soluble in DMSO. The compound is a betulinic acid derivative with improved solubility compared to the parent compound. For storage, it should be kept at 0-4°C for short term or -20°C for long term.
|
| Toxicity/Toxicokinetics |
Toxicological information for NVX-207 is limited to preclinical studies. As a pro-apoptotic agent, it may have effects on normal cells that are actively dividing. Its improved solubility and potency may also affect its toxicity profile. Comprehensive toxicology studies would be required for clinical development, including assessments of hematological, gastrointestinal, and organ toxicity.
|
| References |
[1]. Willmann M, et al. Characterization of NVX-207, a novel betulinic acid-derived anti-cancer compound. Eur J Clin Invest. 2009;39(5):384-394.
[2]. Bache M, et al. Betulinic acid derivatives NVX-207 and B10 for treatment of glioblastoma--an in vitro study of cytotoxicity and radiosensitization. Int J Mol Sci. 2014 Oct 30;15(11):19777-90 |
| Additional Infomation |
NVX-207 is a semi-synthetic derivative of betulinic acid with anti-cancer activity. It is being investigated for the treatment of actinic keratosis and other cancers. The compound shows improved solubility and enhanced pro-apoptotic potency compared to betulinic acid. It is available from research chemical suppliers for preclinical studies. It is not approved for clinical use.
|
| Molecular Formula |
C36H59NO6
|
|---|---|
| Molecular Weight |
601.86
|
| Exact Mass |
601.434
|
| CAS # |
745020-66-0
|
| PubChem CID |
9960374
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
664.8±55.0 °C at 760 mmHg
|
| Flash Point |
355.8±31.5 °C
|
| Vapour Pressure |
0.0±4.6 mmHg at 25°C
|
| Index of Refraction |
1.553
|
| LogP |
9.76
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
43
|
| Complexity |
1130
|
| Defined Atom Stereocenter Count |
10
|
| SMILES |
O(C(C([H])([H])[H])=O)[C@@]1([H])C([H])([H])C([H])([H])[C@@]2(C([H])([H])[H])[C@]([H])(C1(C([H])([H])[H])C([H])([H])[H])C([H])([H])C([H])([H])[C@]1(C([H])([H])[H])[C@]2([H])C([H])([H])C([H])([H])[C@]2([H])[C@@]3([H])[C@]([H])(C(=C([H])[H])C([H])([H])[H])C([H])([H])C([H])([H])[C@]3(C(=O)OC([H])([H])C(C([H])([H])O[H])(C([H])([H])O[H])N([H])[H])C([H])([H])C([H])([H])[C@@]12C([H])([H])[H]
|
| InChi Key |
KQZVSTAVTJCKDG-DRSBITMPSA-N
|
| InChi Code |
InChI=1S/C36H59NO6/c1-22(2)24-11-16-36(30(41)42-21-35(37,19-38)20-39)18-17-33(7)25(29(24)36)9-10-27-32(6)14-13-28(43-23(3)40)31(4,5)26(32)12-15-34(27,33)8/h24-29,38-39H,1,9-21,37H2,2-8H3/t24-,25+,26-,27+,28-,29+,32-,33+,34+,36-/m0/s1
|
| Chemical Name |
[2-amino-3-hydroxy-2-(hydroxymethyl)propyl] (1R,3aS,5aR,5bR,7aR,9S,11aR,11bR,13aR,13bR)-9-acetyloxy-5a,5b,8,8,11a-pentamethyl-1-prop-1-en-2-yl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysene-3a-carboxylate
|
| Synonyms |
NVX 207 NVX207 NVX-207
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~125 mg/mL (~207.69 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (3.46 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (3.46 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (3.46 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6615 mL | 8.3076 mL | 16.6152 mL | |
| 5 mM | 0.3323 mL | 1.6615 mL | 3.3230 mL | |
| 10 mM | 0.1662 mL | 0.8308 mL | 1.6615 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
